Drugs / HS-10511
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06210607 | Jan → Jun 2024 | hypertrophic cardiomyopathy | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06210607 ↗ |
| Route | Oral | “administered as single oral dose and multiple oral doses” NCT06210607 ↗ |